As of April 17, 2026, Marker Therapeutics's top three insider holders are Juan Vera (Chief Scientific Officer Coo, 2.67Mn shares), Enterprise Associates 16, L.P. New (TenPercentOwner, 1.63Mn shares), Enterprise Associates 16, L.P. New (TenPercentOwner, 1.63Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Juan Vera | Chief Scientific Officer Coo | 2,671,845 | 0 | 28 Mar, 2022 |
| Enterprise Associates 16, L.P. New | - | 1,625,678 | 0 | 23 Dec, 2024 |
| Enterprise Associates 16, L.P. New | - | 1,625,678 | 0 | 23 Dec, 2024 |
| Enterprise Associates 16, L.P. New | - | 1,625,678 | 0 | 23 Dec, 2024 |
| Enterprise Associates 16, L.P. New | - | 1,625,678 | 0 | 23 Dec, 2024 |
| Peter L. Hoang | President And Ceo | 483,286 | 0 | 28 Mar, 2022 |
| Steve Elms | - | 0 | 325,370 | 26 Dec, 2024 |
| Anthony H. Kim | Chief Financial Officer | 114,436 | 0 | 28 Mar, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Nov, 2025 | Steve Elms | Stock Option (right to buy) | A | 84,411 | $0.00 | 84,411 | D | A |
| 17 Nov, 2025 | Norman David Eansor | Stock Option (Right to Buy) | A | 84,411 | $0.00 | 84,411 | D | A |
| 17 Nov, 2025 | Katharine Knobil | Stock Option (Right to Buy) | A | 84,411 | $0.00 | 84,411 | D | A |
| 17 Nov, 2025 | Steve Elms | Stock Option (right to buy) | A | 137,330 | $0.00 | 137,330 | D | A |
| 17 Nov, 2025 | Katharine Knobil | Stock Option (Right to Buy) | A | 137,330 | $0.00 | 137,330 | D | A |
| 17 Nov, 2025 | Norman David Eansor | Stock Option (Right to Buy) | A | 137,330 | $0.00 | 137,330 | D | A |
| 31 Oct, 2025 | Juan Vera | Employee Stock Option (right to buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 31 Oct, 2025 | Kathryn Penkus Corzo | Stock Option (Right to Buy) | A | 147,611 | $0.00 | 147,611 | D | A |
| 12 Feb, 2025 | Steve Elms | Stock Option (right to buy) | A | 30,000 | $0.00 | 30,000 | D | A |
| 12 Feb, 2025 | Katharine Knobil | Stock Option (right to buy) | A | 30,000 | $0.00 | 30,000 | D | A |
| 12 Feb, 2025 | Norman David Eansor | Stock Option (right to buy) | A | 30,000 | $0.00 | 30,000 | D | A |
| 12 Feb, 2025 | Juan Vera | Employee Stock Option (right to buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 23 Dec, 2024 | Steve Elms | Common Stock | A | 11,085 | $3.20 | 325,370 | I | P |
| 23 Dec, 2024 | Enterprise Associates 16, L.P. New | Common Stock | A | 554,250 | $3.20 | 1,625,678 | D | P |
| 06 Jun, 2023 | John Robert Wilson | Stock Option (right to buy) | A | 8,000 | $0.00 | 8,000 | D | A |
| 06 Jun, 2023 | Steve Elms | Stock Option (right to buy) | A | 8,000 | $0.00 | 8,000 | D | A |
| 06 Jun, 2023 | Katharine Knobil | Stock Option (right to buy) | A | 8,000 | $0.00 | 8,000 | D | A |
| 10 May, 2023 | Juan Vera | Employee Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 27 Feb, 2023 | Anna Szymanska | Employee Stock Option (right to buy) | A | 29,947 | $0.00 | 29,947 | D | A |
| 27 Feb, 2023 | Michael Loiacono | Employee Stock Option (right to buy) | A | 38,480 | $0.00 | 38,480 | D | A |